Inversely, NSCLC patients with PTdeep-related PD-L1 TPS ≥50% could hold a substantially higher ORR than those with TPS <50% (52.4% (4/23) vs. 17.4% (11/21), P = 0.025) (Figure 4A, B). The gene discussed is CD274; the disease is non-small cell lung carcinoma.